These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 18094402)

  • 21. Angiogenesis--a new target for future therapy.
    Pandya NM; Dhalla NS; Santani DD
    Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions.
    Hainaud P; Contrerès JO; Villemain A; Liu LX; Plouët J; Tobelem G; Dupuy E
    Cancer Res; 2006 Sep; 66(17):8501-10. PubMed ID: 16951162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.
    Noguera-Troise I; Daly C; Papadopoulos NJ; Coetzee S; Boland P; Gale NW; Lin HC; Yancopoulos GD; Thurston G
    Novartis Found Symp; 2007; 283():106-20; discussion 121-5, 238-41. PubMed ID: 18300417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching.
    Suchting S; Freitas C; le Noble F; Benedito R; Bréant C; Duarte A; Eichmann A
    Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3225-30. PubMed ID: 17296941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
    Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
    Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer.
    Oishi H; Sunamura M; Egawa S; Motoi F; Unno M; Furukawa T; Habib NA; Yagita H
    Pancreas; 2010 Aug; 39(6):897-903. PubMed ID: 20182391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy.
    Greenberg JI; Cheresh DA
    Expert Opin Biol Ther; 2009 Nov; 9(11):1347-56. PubMed ID: 19761418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies.
    Sainson RC; Harris AL
    Angiogenesis; 2008; 11(1):41-51. PubMed ID: 18256896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
    Epstein RJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
    Shibuya M
    FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
    Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
    Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Agent-based simulation of notch-mediated tip cell selection in angiogenic sprout initialisation.
    Bentley K; Gerhardt H; Bates PA
    J Theor Biol; 2008 Jan; 250(1):25-36. PubMed ID: 18028963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical implications of angiogenesis in the treatment of cancer.
    Aoun E; Taher A
    J Med Liban; 2002; 50(1-2):32-8. PubMed ID: 12841311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.
    Griffioen AW; Molema G
    Pharmacol Rev; 2000 Jun; 52(2):237-68. PubMed ID: 10835101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis.
    Larsen AK; Ouaret D; El Ouadrani K; Petitprez A
    Pharmacol Ther; 2011 Jul; 131(1):80-90. PubMed ID: 21439312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of Notch ligand Dll1 in B16 melanoma cells leads to reduced tumor growth due to attenuated vascularization.
    Zhang JP; Qin HY; Wang L; Liang L; Zhao XC; Cai WX; Wei YN; Wang CM; Han H
    Cancer Lett; 2011 Oct; 309(2):220-7. PubMed ID: 21752535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.